968 Shares in Penumbra, Inc. (NYSE:PEN) Bought by Seeds Investor LLC

Seeds Investor LLC acquired a new position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 968 shares of the company's stock, valued at approximately $230,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new position in Penumbra during the 4th quarter worth approximately $573,000. E. Ohman J or Asset Management AB lifted its stake in Penumbra by 10.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company's stock valued at $5,061,000 after acquiring an additional 2,000 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Penumbra by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company's stock worth $64,493,000 after acquiring an additional 3,807 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Penumbra by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 655,572 shares of the company's stock worth $127,417,000 after acquiring an additional 11,257 shares in the last quarter. Finally, Washington Capital Management Inc. bought a new stake in shares of Penumbra in the fourth quarter worth $226,000. Institutional investors own 88.88% of the company's stock.

Insider Buying and Selling at Penumbra

In other news, EVP Johanna Roberts sold 600 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total value of $172,458.00. Following the completion of the sale, the executive vice president now directly owns 66,539 shares in the company, valued at $19,125,304.77. This represents a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Maggie Yuen sold 2,000 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $286.00, for a total value of $572,000.00. Following the completion of the transaction, the chief financial officer now directly owns 15,243 shares of the company's stock, valued at approximately $4,359,498. This trade represents a 11.60 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 111,286 shares of company stock valued at $31,235,951. Insiders own 5.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PEN shares. JPMorgan Chase & Co. increased their price objective on Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. UBS Group increased their price target on shares of Penumbra from $305.00 to $320.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Canaccord Genuity Group upped their target price on shares of Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Royal Bank of Canada reiterated an "outperform" rating and set a $315.00 price target on shares of Penumbra in a report on Tuesday. Finally, Wells Fargo & Company upped their price objective on Penumbra from $275.00 to $305.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $293.93.

Penumbra Stock Down 0.4 %

Shares of Penumbra stock traded down $1.17 during trading on Friday, hitting $276.62. The company's stock had a trading volume of 326,817 shares, compared to its average volume of 413,437. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The company has a market capitalization of $10.70 billion, a PE ratio of 813.60, a P/E/G ratio of 2.83 and a beta of 0.56. The company has a fifty day simple moving average of $275.31 and a two-hundred day simple moving average of $250.67.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Equities research analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.